Genetic Analysis AS: Mandatory notification of trade
OSLO, NORWAY – 20 November 2023: Genetic Analysis AS (“GA” or “the Company”) announces that members of the Board and Management have been allocated GEAN shares in connection with the direct issue approved by the Company's extraordinary general meeting today.
In connection with the directed issue of new shares in the Company with gross proceeds of in aggregate approximately NOK 10.5 million (the "Directed Issue") approved by the Company's extraordinary general meeting today, 20 November 2023, the following persons discharging managerial responsibilities and their close associates, including members of the Board of Directors and management of the Company, have been allocated shares in the Directed Issue:
Per Matsson, Chairperson of the Board in Genetic Analysis AS, has today been allocated 126,582 GEAN-shares at a price of 0.79 NOK per share. After the transaction, Per Matsson owns 156,582 shares and 225.000 share options in Genetic Analysis AS.
Camilla Huse Bondesson, Board member in Genetic Analysis AS, has today been allocated 126,582 -shares at a price of 0.79 NOK per share. Camilla Huse Bondesson owns 165,042 shares and 70.000 options following the transaction.
Ronny Hermansen, CEO in Genetic Analysis AS, has through the fully owned company InVitroDia AS today been allocated 356,962 GEAN-shares at a price of 0.79 NOK per share. Ronny Hermansen including controlled company owns 582,252 shares and 566.668 options following the transaction.
Christina Casén, SVP Medical & Clinical Affairs in Genetic Analysis AS, has today been allocated 73,417 GEAN-shares at a price of 0.79 NOK per share. Christina Casén owns 160,489 shares and 210.000 options following the transaction.
Lars Tiller, Head of Operations in Genetic Analysis AS, has today been allocated 63,291 GEAN-shares at a price of 0.79 NOK per share. Lars Tiller owns 63,291 shares and 60.000 options following the transaction.
Kari Furu, Head of Product and Business Development in Genetic Analysis AS, has today been allocated 63,291 GEAN-shares at a price of 0.79 NOK per share. Kari Furu owns 73,291 shares and 126.667 options following the transaction.
Eilert Aamodt, CFO in Genetic Analysis AS, has through the fully owned company E. B. Aamodt AS today been allocated 75,949 GEAN-shares at a price of 0.79 NOK per share. Eilert Aamodt including controlled company owns 124,409 shares and 156.667 options following the transaction.
Reference is also made to the attached forms of notification and public disclosure by persons discharging managerial responsibilities and persons closely associated with them.
This information is subject to the disclosure requirements in Article 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation).
